Pharmacist tailored monitoring for patients initiating encorafenib and binimetinib combination therapy
Journal of Oncology Pharmacy Practice
Published online on April 23, 2025
Abstract
Journal of Oncology Pharmacy Practice, Ahead of Print.
Introduction:Combination therapy with protein kinase B-raf (BRAF) inhibitor, encorafenib, and mitogen-activated extracellular kinase (MEK) inhibitor, binimetinib, is associated with adverse events (AEs) that can lead to therapy changes early in ...
Introduction:Combination therapy with protein kinase B-raf (BRAF) inhibitor, encorafenib, and mitogen-activated extracellular kinase (MEK) inhibitor, binimetinib, is associated with adverse events (AEs) that can lead to therapy changes early in ...